Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome

Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outs...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2016-01, Vol.21 (5), p.455-459
Main Authors: Kim, Uh Jin, Won, Eun-Jeong, Kee, Seung-Jung, Jung, Sook-In, Jang, Hee-Chang
Format: Article
Language:English
Subjects:
Antiviral Agents - administration & dosage
Coronavirus Infections - diagnostic imaging
Coronavirus Infections - drug therapy
Coronavirus Infections - virology
Drug Therapy, Combination
Humans
Interferon-alpha - administration & dosage
Lopinavir - administration & dosage
Male
Middle Aged
Middle East Respiratory Syndrome Coronavirus - drug effects
Middle East Respiratory Syndrome Coronavirus - genetics
Middle East Respiratory Syndrome Coronavirus - isolation & purification
Republic of Korea
Ribavirin - administration & dosage
Ritonavir - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c315t-902fc525e71ecf5ee9541b453164fb54ea5c9f5f18deaf0097a9417285479e4f3
cites cdi_FETCH-LOGICAL-c315t-902fc525e71ecf5ee9541b453164fb54ea5c9f5f18deaf0097a9417285479e4f3
container_end_page 459
container_issue 5
container_start_page 455
container_title Antiviral therapy
container_volume 21
creator Kim, Uh Jin
Won, Eun-Jeong
Kee, Seung-Jung
Jung, Sook-In
Jang, Hee-Chang
description Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outside of the Middle East. The combination of ribavirin and interferon-α has been the most widely used therapy for this infection. However, due to the varying results of treatment with these drugs, a new antiviral combination regimen is urgently needed. This is a case report of use of lopinavir/ritonavir-based combination antiviral therapy for a patient with MERS-CoV infection.
doi_str_mv 10.3851/IMP3002
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1855079126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1855079126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c315t-902fc525e71ecf5ee9541b453164fb54ea5c9f5f18deaf0097a9417285479e4f3</originalsourceid><addsrcrecordid>eNqN0TtOxDAQBmALgWB5iBsgd1AQsB3PJi7RipcEggLqyEnGwiixg-0F7bG4CGciyy7UVPNr9OkvZgg55OwsL4Gf394_5oyJDTIRTLJMMCg3yYTnoLIp5LBDdmN8HUGpGNsmO2IqlRBcTYib-b62TifrHU0vGPSwoB82vdDOD-P-3YbzYJP_Sac02HoZrKPatdS6hMFg8C77-qTGB3pv27ZDeqljogHjYINOPixoXLg2-B73yZbRXcSD9dwjz1eXT7Ob7O7h-nZ2cZc1OYeUKSZMAwKw4NgYQFQgeS0h51NpapCooVEGDC9b1IYxVWgleSFKkIVCafI9crLqHYJ_m2NMVW9jg12nHfp5rHgJwArFxfQfVPBR8qIY6fGKNsHHGNBUQ7C9DouKs2r5h2r9h1EerUvndY_tn_s9fP4NqQyEXw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1821791177</pqid></control><display><type>article</type><title>Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome</title><source>SAGE Open Access</source><creator>Kim, Uh Jin ; Won, Eun-Jeong ; Kee, Seung-Jung ; Jung, Sook-In ; Jang, Hee-Chang</creator><creatorcontrib>Kim, Uh Jin ; Won, Eun-Jeong ; Kee, Seung-Jung ; Jung, Sook-In ; Jang, Hee-Chang</creatorcontrib><description>Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outside of the Middle East. The combination of ribavirin and interferon-α has been the most widely used therapy for this infection. However, due to the varying results of treatment with these drugs, a new antiviral combination regimen is urgently needed. This is a case report of use of lopinavir/ritonavir-based combination antiviral therapy for a patient with MERS-CoV infection.</description><identifier>ISSN: 1359-6535</identifier><identifier>EISSN: 2040-2058</identifier><identifier>DOI: 10.3851/IMP3002</identifier><identifier>PMID: 26492219</identifier><language>eng</language><publisher>England</publisher><subject><![CDATA[Antiviral Agents - administration & dosage ; Coronavirus Infections - diagnostic imaging ; Coronavirus Infections - drug therapy ; Coronavirus Infections - virology ; Drug Therapy, Combination ; Humans ; Interferon-alpha - administration & dosage ; Lopinavir - administration & dosage ; Male ; Middle Aged ; Middle East Respiratory Syndrome Coronavirus - drug effects ; Middle East Respiratory Syndrome Coronavirus - genetics ; Middle East Respiratory Syndrome Coronavirus - isolation & purification ; Republic of Korea ; Ribavirin - administration & dosage ; Ritonavir - administration & dosage]]></subject><ispartof>Antiviral therapy, 2016-01, Vol.21 (5), p.455-459</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c315t-902fc525e71ecf5ee9541b453164fb54ea5c9f5f18deaf0097a9417285479e4f3</citedby><cites>FETCH-LOGICAL-c315t-902fc525e71ecf5ee9541b453164fb54ea5c9f5f18deaf0097a9417285479e4f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26492219$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Uh Jin</creatorcontrib><creatorcontrib>Won, Eun-Jeong</creatorcontrib><creatorcontrib>Kee, Seung-Jung</creatorcontrib><creatorcontrib>Jung, Sook-In</creatorcontrib><creatorcontrib>Jang, Hee-Chang</creatorcontrib><title>Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome</title><title>Antiviral therapy</title><addtitle>Antivir Ther</addtitle><description>Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outside of the Middle East. The combination of ribavirin and interferon-α has been the most widely used therapy for this infection. However, due to the varying results of treatment with these drugs, a new antiviral combination regimen is urgently needed. This is a case report of use of lopinavir/ritonavir-based combination antiviral therapy for a patient with MERS-CoV infection.</description><subject>Antiviral Agents - administration &amp; dosage</subject><subject>Coronavirus Infections - diagnostic imaging</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - virology</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Interferon-alpha - administration &amp; dosage</subject><subject>Lopinavir - administration &amp; dosage</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Middle East Respiratory Syndrome Coronavirus - drug effects</subject><subject>Middle East Respiratory Syndrome Coronavirus - genetics</subject><subject>Middle East Respiratory Syndrome Coronavirus - isolation &amp; purification</subject><subject>Republic of Korea</subject><subject>Ribavirin - administration &amp; dosage</subject><subject>Ritonavir - administration &amp; dosage</subject><issn>1359-6535</issn><issn>2040-2058</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqN0TtOxDAQBmALgWB5iBsgd1AQsB3PJi7RipcEggLqyEnGwiixg-0F7bG4CGciyy7UVPNr9OkvZgg55OwsL4Gf394_5oyJDTIRTLJMMCg3yYTnoLIp5LBDdmN8HUGpGNsmO2IqlRBcTYib-b62TifrHU0vGPSwoB82vdDOD-P-3YbzYJP_Sac02HoZrKPatdS6hMFg8C77-qTGB3pv27ZDeqljogHjYINOPixoXLg2-B73yZbRXcSD9dwjz1eXT7Ob7O7h-nZ2cZc1OYeUKSZMAwKw4NgYQFQgeS0h51NpapCooVEGDC9b1IYxVWgleSFKkIVCafI9crLqHYJ_m2NMVW9jg12nHfp5rHgJwArFxfQfVPBR8qIY6fGKNsHHGNBUQ7C9DouKs2r5h2r9h1EerUvndY_tn_s9fP4NqQyEXw</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Kim, Uh Jin</creator><creator>Won, Eun-Jeong</creator><creator>Kee, Seung-Jung</creator><creator>Jung, Sook-In</creator><creator>Jang, Hee-Chang</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20160101</creationdate><title>Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome</title><author>Kim, Uh Jin ; Won, Eun-Jeong ; Kee, Seung-Jung ; Jung, Sook-In ; Jang, Hee-Chang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c315t-902fc525e71ecf5ee9541b453164fb54ea5c9f5f18deaf0097a9417285479e4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antiviral Agents - administration &amp; dosage</topic><topic>Coronavirus Infections - diagnostic imaging</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - virology</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Interferon-alpha - administration &amp; dosage</topic><topic>Lopinavir - administration &amp; dosage</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Middle East Respiratory Syndrome Coronavirus - drug effects</topic><topic>Middle East Respiratory Syndrome Coronavirus - genetics</topic><topic>Middle East Respiratory Syndrome Coronavirus - isolation &amp; purification</topic><topic>Republic of Korea</topic><topic>Ribavirin - administration &amp; dosage</topic><topic>Ritonavir - administration &amp; dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Uh Jin</creatorcontrib><creatorcontrib>Won, Eun-Jeong</creatorcontrib><creatorcontrib>Kee, Seung-Jung</creatorcontrib><creatorcontrib>Jung, Sook-In</creatorcontrib><creatorcontrib>Jang, Hee-Chang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Antiviral therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Uh Jin</au><au>Won, Eun-Jeong</au><au>Kee, Seung-Jung</au><au>Jung, Sook-In</au><au>Jang, Hee-Chang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome</atitle><jtitle>Antiviral therapy</jtitle><addtitle>Antivir Ther</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>21</volume><issue>5</issue><spage>455</spage><epage>459</epage><pages>455-459</pages><issn>1359-6535</issn><eissn>2040-2058</eissn><abstract>Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outside of the Middle East. The combination of ribavirin and interferon-α has been the most widely used therapy for this infection. However, due to the varying results of treatment with these drugs, a new antiviral combination regimen is urgently needed. This is a case report of use of lopinavir/ritonavir-based combination antiviral therapy for a patient with MERS-CoV infection.</abstract><cop>England</cop><pmid>26492219</pmid><doi>10.3851/IMP3002</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1359-6535
ispartof Antiviral therapy, 2016-01, Vol.21 (5), p.455-459
issn 1359-6535
2040-2058
language eng
recordid cdi_proquest_miscellaneous_1855079126
source SAGE Open Access
subjects Antiviral Agents - administration & dosage
Coronavirus Infections - diagnostic imaging
Coronavirus Infections - drug therapy
Coronavirus Infections - virology
Drug Therapy, Combination
Humans
Interferon-alpha - administration & dosage
Lopinavir - administration & dosage
Male
Middle Aged
Middle East Respiratory Syndrome Coronavirus - drug effects
Middle East Respiratory Syndrome Coronavirus - genetics
Middle East Respiratory Syndrome Coronavirus - isolation & purification
Republic of Korea
Ribavirin - administration & dosage
Ritonavir - administration & dosage
title Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T13%3A33%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20therapy%20with%20lopinavir/ritonavir,%20ribavirin%20and%20interferon-%CE%B1%20for%20Middle%20East%20respiratory%20syndrome&rft.jtitle=Antiviral%20therapy&rft.au=Kim,%20Uh%20Jin&rft.date=2016-01-01&rft.volume=21&rft.issue=5&rft.spage=455&rft.epage=459&rft.pages=455-459&rft.issn=1359-6535&rft.eissn=2040-2058&rft_id=info:doi/10.3851/IMP3002&rft_dat=%3Cproquest_cross%3E1855079126%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c315t-902fc525e71ecf5ee9541b453164fb54ea5c9f5f18deaf0097a9417285479e4f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1821791177&rft_id=info:pmid/26492219&rfr_iscdi=true